NovoCure (NVCR) Receivables - Other (2022 - 2026)

NovoCure has disclosed Receivables - Other across 5 years of filings, most recently posting $8.2 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $8.2 million, up 25.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.2 million (up 25.64% YoY), and the FY2025 annual result was $7.8 million, up 36.02% from the prior year.
• Receivables - Other came in at $8.2 million for Q1 2026 at NovoCure, up from $7.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $8.2 million in Q1 2026 to a low of $2.2 million in Q4 2022.
• The 5-year median for Receivables - Other is $5.7 million (2024), against an average of $5.8 million.
• Across the five-year window, Receivables - Other soared 93.93% in 2023 and grew 25.64% in 2026, its largest moves.
• NovoCure's Receivables - Other stood at $2.2 million in 2022, then surged by 93.93% to $4.3 million in 2023, then surged by 34.67% to $5.7 million in 2024, then jumped by 36.02% to $7.8 million in 2025, then advanced by 5.89% to $8.2 million in 2026.
• The last three Receivables - Other figures came in at $8.2 million (Q1 2026), $7.8 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.